NKX101, an Allogeneic Off-the-Shelf CAR NK Therapy Targeting NKG2D-Ls, Has Potent In Vitro Cytotoxicity Against Patient-Derived AML Leukemic Stem Cell (LSC) and Non-Leukemic Stem Cell (Non-LSC) Blasts

被引：0

|

作者：

Hansen, Kyle ^{[1
]}

Cho, Cynthia ^{[1
]}

Mehta, Nishi ^{[1
]}

Shook, David ^{[1
]}

Trager, James ^{[1
]}

机构：

[1] Nkarta, San Francisco, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-190214

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页数：3

相关论文

共 4 条

[1] NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blasts
Hansen, Kyle
Cho, Cynthia
Kothari, Nishi
Shook, David
Trager, James
CANCER RESEARCH, 2024, 84 (06)
[2] NKX101, an Allogeneic Off-the-Shelf CAR NK Cell Therapy Targeting NKG2D-Ls, Has Potent Anti-Leukemic Activity Alone or in Combination with Ara-C
Cho, Cynthia
Hansen, Kyle
Kimura, Nikki
Sood, Jessica
Juat, Damie
Geng, Tao
Trager, James
BLOOD, 2023, 142
[3] NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-C
Cho, Cynthia
Kimura, Nikki
Sood, Jessica
Juat, Damie
Zhang, Max
Chan, Carmel
Geng, Tao
Hansen, Kyle
Trager, James
CANCER RESEARCH, 2024, 84 (06)
[4] Combination of anti-EGFR antibody cetuximab with NKX101, an allogeneic NKG2D-L targeting NK cell therapy, enhances potency and in vitro cytotoxicity against solid tumors
Cho, Cynthia
Hansen, Kyle
Zhang, Max
Chan, Carmel
Trager, James
CANCER RESEARCH, 2023, 83 (07)